Pharmacogenomics

Challenges and opportunities

Dan M. Roden, Russ B. Altman, Neal L. Benowitz, David A. Flockhart, Kathleen M. Giacomini, Julie A. Johnson, Ronald M. Krauss, Howard L. McLeod, Mark J. Ratain, Mary V. Relling, Huijun Z. Ring, Alan R. Shuldiner, Richard M. Weinshilboum, Scott T. Weiss

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.

Original languageEnglish
Pages (from-to)749-757
Number of pages9
JournalAnnals of Internal Medicine
Volume145
Issue number10
StatePublished - May 15 2006

Fingerprint

Pharmacogenetics
Pharmaceutical Preparations
Genes
Human Genome
Cataloging
Disease Susceptibility
Ethics
Phenotype
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., ... Weiss, S. T. (2006). Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine, 145(10), 749-757.

Pharmacogenomics : Challenges and opportunities. / Roden, Dan M.; Altman, Russ B.; Benowitz, Neal L.; Flockhart, David A.; Giacomini, Kathleen M.; Johnson, Julie A.; Krauss, Ronald M.; McLeod, Howard L.; Ratain, Mark J.; Relling, Mary V.; Ring, Huijun Z.; Shuldiner, Alan R.; Weinshilboum, Richard M.; Weiss, Scott T.

In: Annals of Internal Medicine, Vol. 145, No. 10, 15.05.2006, p. 749-757.

Research output: Contribution to journalArticle

Roden, DM, Altman, RB, Benowitz, NL, Flockhart, DA, Giacomini, KM, Johnson, JA, Krauss, RM, McLeod, HL, Ratain, MJ, Relling, MV, Ring, HZ, Shuldiner, AR, Weinshilboum, RM & Weiss, ST 2006, 'Pharmacogenomics: Challenges and opportunities', Annals of Internal Medicine, vol. 145, no. 10, pp. 749-757.
Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA et al. Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine. 2006 May 15;145(10):749-757.
Roden, Dan M. ; Altman, Russ B. ; Benowitz, Neal L. ; Flockhart, David A. ; Giacomini, Kathleen M. ; Johnson, Julie A. ; Krauss, Ronald M. ; McLeod, Howard L. ; Ratain, Mark J. ; Relling, Mary V. ; Ring, Huijun Z. ; Shuldiner, Alan R. ; Weinshilboum, Richard M. ; Weiss, Scott T. / Pharmacogenomics : Challenges and opportunities. In: Annals of Internal Medicine. 2006 ; Vol. 145, No. 10. pp. 749-757.
@article{6b22e839888d4e5591e9873cc172470b,
title = "Pharmacogenomics: Challenges and opportunities",
abstract = "The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.",
author = "Roden, {Dan M.} and Altman, {Russ B.} and Benowitz, {Neal L.} and Flockhart, {David A.} and Giacomini, {Kathleen M.} and Johnson, {Julie A.} and Krauss, {Ronald M.} and McLeod, {Howard L.} and Ratain, {Mark J.} and Relling, {Mary V.} and Ring, {Huijun Z.} and Shuldiner, {Alan R.} and Weinshilboum, {Richard M.} and Weiss, {Scott T.}",
year = "2006",
month = "5",
day = "15",
language = "English",
volume = "145",
pages = "749--757",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Pharmacogenomics

T2 - Challenges and opportunities

AU - Roden, Dan M.

AU - Altman, Russ B.

AU - Benowitz, Neal L.

AU - Flockhart, David A.

AU - Giacomini, Kathleen M.

AU - Johnson, Julie A.

AU - Krauss, Ronald M.

AU - McLeod, Howard L.

AU - Ratain, Mark J.

AU - Relling, Mary V.

AU - Ring, Huijun Z.

AU - Shuldiner, Alan R.

AU - Weinshilboum, Richard M.

AU - Weiss, Scott T.

PY - 2006/5/15

Y1 - 2006/5/15

N2 - The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.

AB - The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=34447122644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447122644&partnerID=8YFLogxK

M3 - Article

VL - 145

SP - 749

EP - 757

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -